Twist Bioscience Collaborates With Australia Based Specialist Provider For Whole Exome Capture Assay

by Vandana Singh, Benzinga Editor

February 18, 2021 12:44 PM | 1 min read | Make a Comment

Twist Bioscience Corp (NASDAQ: TWST) and Victorian Clinical Genetic Services (VCGS) have developed a novel whole-exome capture assay, which utilizes Next Generation Sequencing to conduct analysis and sequencing of the entire exome.
In particular, the assay can target difficult to cover, non-coding regions outside the normal exome known to contain pathogenic variants. The assay also allows for reanalysis of data when new disease-causing genes are discovered.
VCGS is accredited by Australian authorities to use this assay as an in vitro diagnostic product.
Price Action: TWST is down 1.62% at $152.29 in market trading hours on last check Thursday.

Posted In: News Health Care FDA General

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.